6wew

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Current revision (14:23, 18 October 2023) (edit) (undo)
 
Line 3: Line 3:
<StructureSection load='6wew' size='340' side='right'caption='[[6wew]], [[Resolution|resolution]] 2.73&Aring;' scene=''>
<StructureSection load='6wew' size='340' side='right'caption='[[6wew]], [[Resolution|resolution]] 2.73&Aring;' scene=''>
== Structural highlights ==
== Structural highlights ==
-
<table><tr><td colspan='2'>[[6wew]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6WEW OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=6WEW FirstGlance]. <br>
+
<table><tr><td colspan='2'>[[6wew]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6WEW OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6WEW FirstGlance]. <br>
-
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene>, <scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene>, <scene name='pdbligand=TZV:N-{4-[(7-methoxyquinolin-4-yl)oxy]phenyl}sulfuric+diamide'>TZV</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene></td></tr>
+
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.73&#8491;</td></tr>
-
<tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">ENPP1, M6S1, NPPS, PC1, PDNP1 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
+
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene>, <scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene>, <scene name='pdbligand=TZV:N-{4-[(7-methoxyquinolin-4-yl)oxy]phenyl}sulfuric+diamide'>TZV</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr>
-
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=6wew FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6wew OCA], [http://pdbe.org/6wew PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6wew RCSB], [http://www.ebi.ac.uk/pdbsum/6wew PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6wew ProSAT]</span></td></tr>
+
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6wew FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6wew OCA], [https://pdbe.org/6wew PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6wew RCSB], [https://www.ebi.ac.uk/pdbsum/6wew PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6wew ProSAT]</span></td></tr>
</table>
</table>
== Disease ==
== Disease ==
-
[[http://www.uniprot.org/uniprot/ENPP1_HUMAN ENPP1_HUMAN]] Defects in ENPP1 are a cause of increased susceptibility for ossification of the posterior longitudinal ligament of the spine (OPLL) [MIM:[http://omim.org/entry/602475 602475]]. OPLL is a common form of human myelopathy with a prevalence of as much as 4% in a variety of ethnic groups.<ref>PMID:10453738</ref> Defects in ENPP1 are the cause of arterial calcification of infancy, generalized, type 1 (GACI1) [MIM:[http://omim.org/entry/208000 208000]]. A severe autosomal recessive disorder characterized by calcification of the internal elastic lamina of muscular arteries and stenosis due to myointimal proliferation. The disorder is often fatal within the first 6 months of life because of myocardial ischemia resulting in refractory heart failure.<ref>PMID:12881724</ref> <ref>PMID:15940697</ref> <ref>PMID:15605415</ref> <ref>PMID:22209248</ref> Defects in ENPP1 are associated with obesity, glucose intolerance, and type II diabetes non-insulin dependent (NIDDM) [MIM:[http://omim.org/entry/125853 125853]].<ref>PMID:16186408</ref> Defects in ENPP1 are the cause of rickets hypophosphatemic autosomal recessive type 2 (ARHR2) [MIM:[http://omim.org/entry/613312 613312]]. ARHR2 is a hereditary form of hypophosphatemic rickets, a disorder of proximal renal tubule function that causes phosphate loss, hypophosphatemia and skeletal deformities, including rickets and osteomalacia unresponsive to vitamin D. Symptoms are bone pain, fractures and growth abnormalities.<ref>PMID:20137773</ref> <ref>PMID:20137772</ref>
+
[https://www.uniprot.org/uniprot/ENPP1_HUMAN ENPP1_HUMAN] Defects in ENPP1 are a cause of increased susceptibility for ossification of the posterior longitudinal ligament of the spine (OPLL) [MIM:[https://omim.org/entry/602475 602475]. OPLL is a common form of human myelopathy with a prevalence of as much as 4% in a variety of ethnic groups.<ref>PMID:10453738</ref> Defects in ENPP1 are the cause of arterial calcification of infancy, generalized, type 1 (GACI1) [MIM:[https://omim.org/entry/208000 208000]. A severe autosomal recessive disorder characterized by calcification of the internal elastic lamina of muscular arteries and stenosis due to myointimal proliferation. The disorder is often fatal within the first 6 months of life because of myocardial ischemia resulting in refractory heart failure.<ref>PMID:12881724</ref> <ref>PMID:15940697</ref> <ref>PMID:15605415</ref> <ref>PMID:22209248</ref> Defects in ENPP1 are associated with obesity, glucose intolerance, and type II diabetes non-insulin dependent (NIDDM) [MIM:[https://omim.org/entry/125853 125853].<ref>PMID:16186408</ref> Defects in ENPP1 are the cause of rickets hypophosphatemic autosomal recessive type 2 (ARHR2) [MIM:[https://omim.org/entry/613312 613312]. ARHR2 is a hereditary form of hypophosphatemic rickets, a disorder of proximal renal tubule function that causes phosphate loss, hypophosphatemia and skeletal deformities, including rickets and osteomalacia unresponsive to vitamin D. Symptoms are bone pain, fractures and growth abnormalities.<ref>PMID:20137773</ref> <ref>PMID:20137772</ref>
== Function ==
== Function ==
-
[[http://www.uniprot.org/uniprot/ENPP1_HUMAN ENPP1_HUMAN]] Involved primarily in ATP hydrolysis at the plasma membrane. Plays a role in regulating pyrophosphate levels, and functions in bone mineralization and soft tissue calcification. In vitro, has a broad specificity, hydrolyzing other nucleoside 5' triphosphates such as GTP, CTP, TTP and UTP to their corresponding monophosphates with release of pyrophosphate and diadenosine polyphosphates, and also 3',5'-cAMP to AMP. May also be involved in the regulation of the availability of nucleotide sugars in the endoplasmic reticulum and Golgi, and the regulation of purinergic signaling. Appears to modulate insulin sensitivity.<ref>PMID:10615944</ref>
+
[https://www.uniprot.org/uniprot/ENPP1_HUMAN ENPP1_HUMAN] Involved primarily in ATP hydrolysis at the plasma membrane. Plays a role in regulating pyrophosphate levels, and functions in bone mineralization and soft tissue calcification. In vitro, has a broad specificity, hydrolyzing other nucleoside 5' triphosphates such as GTP, CTP, TTP and UTP to their corresponding monophosphates with release of pyrophosphate and diadenosine polyphosphates, and also 3',5'-cAMP to AMP. May also be involved in the regulation of the availability of nucleotide sugars in the endoplasmic reticulum and Golgi, and the regulation of purinergic signaling. Appears to modulate insulin sensitivity.<ref>PMID:10615944</ref>
<div style="background-color:#fffaf0;">
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
== Publication Abstract from PubMed ==
Line 21: Line 21:
</div>
</div>
<div class="pdbe-citations 6wew" style="background-color:#fffaf0;"></div>
<div class="pdbe-citations 6wew" style="background-color:#fffaf0;"></div>
 +
 +
==See Also==
 +
*[[Ectonucleotide pyrophosphatase/phosphodiesterase 3D structures|Ectonucleotide pyrophosphatase/phosphodiesterase 3D structures]]
== References ==
== References ==
<references/>
<references/>
__TOC__
__TOC__
</StructureSection>
</StructureSection>
-
[[Category: Human]]
+
[[Category: Homo sapiens]]
[[Category: Large Structures]]
[[Category: Large Structures]]
-
[[Category: Dennis, M]]
+
[[Category: Dennis M]]
-
[[Category: Newman, J]]
+
[[Category: Newman J]]
-
[[Category: Peat, T S]]
+
[[Category: Peat TS]]
-
[[Category: Drug discovery]]
+
-
[[Category: Human e-npp 1]]
+
-
[[Category: Hydrolase-hydrolase inhibitor complex]]
+
-
[[Category: Inhibitor]]
+

Current revision

Crystal structures of human E-NPP 1: bound to N-{4-[(7-methoxyquinolin-4-yl)oxy]phenyl}sulfuric diamide

PDB ID 6wew

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools